Found 1 Presentation For Request "1217p"
1217P - EGFR TKIs in patients (pts) with NSCLC with uncommon EGFR mutations: A real-world cohort study (UpSwinG)
- Satoru Miura (Niigata, Japan)
Abstract
Background
Despite being an established treatment (tx) option in pts with
Methods
In this non-interventional, global study (NCT04179890), existing medical/electronic records were searched for consecutive EGFR TKI-naïve (at diagnosis) pts with uncommon
Results
Pts (n=246; median age: 69.5 years; female: 56%; Asian: 90%; brain metastases: 8%; ECOG PS ≥2: 16%) were recruited from 36 sites in 9 countries. Most pts (n=226, 92%) received EGFR TKIs as 1st-line tx (afatinib: n=126, 56%; 1st-gen EGFR TKI: n=93, 41%; osimertinib: n=5, 2%; combination: n=2, 1%). EGFR TKIs received as 2nd-line tx (n=52) were: afatinib (n=11, 21%), 1st-gen EGFR TKIs (n=20, 38%) and osimertinib (n=21, 40%). Median duration of 1st-line EGFR TKI tx was 10.4 mos. From the start of 1st- to the start of 2nd-line tx, ECOG PS was stable/improved/deteriorated in 73/9/18% of pts. Overall, median TTF, OS, and DoR with EGFR TKIs was 9.9, 24.4 and 10.0 mos, and ORR was 43%. Strongest responses were seen in pts with major uncommon and/or compound mutations (Table). In the major uncommon group, median TTF and OS in pts with brain metastases was 17.3 and 33.9 mos, and with ECOG PS ≥2 was 8.6 and 14.3 mos.
Conclusions
In a real-world setting, EGFR TKIs were the tx of choice in pts with uncommon
Pts treated with afatinib as index line therapy Median TTF, mos Median OS, mos ORR (evaluable pts), % Median DoR, mos All (n=132) 11.3 24.5 43.8 12.0 Major uncommon (n=94) 14.3 24.5 50.6 12.0 Compound (n=46) 12.6 23.4 52.5 10.0 ‘Other’ (n=9) 10.8 20.2 28.6 10.5 Ex20ins (n=18) 8.3 22.5 18.8 5.5 All (n=106) 8.8 24.2 44.1 6.0 Major uncommon (n=80) 9.8 28.5 47.3 6.5 Compound (n=32) 12.4 31.3 43.8 6.0 ‘Other’ (n=12) 7.3 12.8 55.6 4.5 Ex20ins (n=10) 5.2 21.0 16.7 3.0
Clinical trial identification
NCT04179890.
Editorial acknowledgement
Medical writing assistance, supported financially by Boehringer Ingelheim Pharmaceuticals Inc., was provided by Steven Kirkham of Ashfield MedComms, an Ashfield Health Company, during the preparation of this abstract.
Legal entity responsible for the study
Boehringer Ingelheim.
Funding
Boehringer Ingelheim.
Disclosure
S. Miura: Financial Interests, Personal, Speaker’s Bureau, Speaker bureau fees/Expert testimony: Boehringer Ingelheim Inc.; Financial Interests, Personal, Speaker’s Bureau, Speaker bureau fees/Expert testimony: MSD Inc.; Financial Interests, Personal, Speaker’s Bureau, Speaker bureau fees/Expert testimony: Elli Lilly Japan; Financial Interests, Personal, Speaker’s Bureau, Speaker bureau fees/Expert testimony: Ono Pharma. Inc.; Financial Interests, Personal, Speaker’s Bureau, Speaker bureau fees/Expert testimony: Chugai Pharm Inc